This was consistent with the results from Zhou et al. showing that the common treatment-related adverse events in PD-1 or PD-L1 inhibitors and chemotherapy combination was anemia (45.4%) of all-grade adverse events and neutropenia (19.6%) of grade 3 or higher [21]. This evidence concerns the gene PDCD1 and neutropenia.